'Bad cholesterol' drug firm Amryt Pharma has reported revenue of $113.1m (€101m) for the nine months to 30 September, up from $94.5m (€84.6m) in the same period last year. 'Bad cholesterol' drug firm Amryt Pharma has reported revenue of $113.1m (€101m) for the nine months to 30 September, up from $94.5m (€84.6m) in the same period last year. Revenue increases at Amryt Pharma on the back of acquisitionsThe performance was helped by the company’s acquisition of Aegerion Pharmaceuticals, a former subsidiary of Novelion Therapeutics. At 31 October the group had cash on hand of $61.2m, according to a trading update from the company. Dr Joe Wiley, CEO of Amryt Pharma, said: "The first nine months of 2019 have been momentous and transformational for Amryt.

Source: Irish Independent November 05, 2019 08:37 UTC